Graham Purdy
Analyst · The Benchmark Company
Thanks, Andrew. With all that said, good morning, everyone, and thank you for joining our call. Our first quarter results were in line with, and in some cases, better than our expectations and demonstrated continued progress against our plan. Adjusted EBITDA increased 21.6% to $25.3 million for the quarter. During the March quarter, Zig-Zag performed very well with revenue up 11.5% to $46.7 million, driven by strong double-digit growth in our Zig-Zag papers and alternative channel business.
As we mentioned last quarter, we think we're past the noise associated with the trade inventory rationalizations we discussed last year, and we anticipate the backdrop is favorable for growth in 2024, and we demonstrated just that in Q1. We are encouraged by our wholesale customers and retail customers response to our expanding portfolio and some of our recent new product introductions.
We remain committed to our alternative channel strategy and are efficiently filling out our customers' portfolio to better satisfy the growing and evolving demand from end consumers. Both factors are expanding our addressable market. We are having success not only winning new untapped alternative customers across the brick-and-mortar and alternative distributor network, but we are also seeing existing old customers buy a more complete Zig-Zag portfolio. As a result, we've seen healthy increases in average order sizes across the alternative space while providing the Zig-Zag brand with more valuable shelf space and merchandising real estate within these stores to build brand awareness as we satisfy evolving in consumer preferences.
Considering that many of our competitors offer far fewer SKUs than Zig-Zag, we're finding that the alt channel is actively looking for partners that provide service above and beyond ordinary fulfillment, and we are one of the few companies that can truly meet the needs of the evolving end customer. In addition to our full suite of product offerings from a well-known brand like Zig-Zag from papers, cones, accessories and apparel, there is a growing appetite to sell our wraps, cigars and Modern Oral nicotine in stores and distributors that cater to this growing channel.
As you know, the alternative channel is consistently expanding by virtue of additional states greenlighting medical and recreational cannabis as well as attempts to provide a better shopping experience for consumers. In addition to more legal dispensaries and manufacturing and processing facilities, other retail outlets like head shops are drafting off this trend. Our alternative B2B business saw continued momentum in Q1, accelerating from the growth we saw throughout 2023, growing over 60% in the quarter.
Moving to Stoker's. During the quarter, Stoker's revenue increased 8% to $36.4 million, reflecting a 4.6% decline in loose leaf and a 6.7% increase in MST. Please recall that for the fourth quarter of 2023, we called out a likely unsustainable 18.6% increase in total Stoker's revenue. We continue to be pleased with the market share increases for Stoker's, which continues to be a steady growth engine with a long runway for volume growth and favorable pricing dynamics.
We are pleased with the market's enthusiastic response to the beginning of our national launch of FRE, our Modern Oral, so-called white pouch product. As you can appreciate, given that we are in the early innings of growing our presence in this category, we will limit specific operating metrics around FRE. However, we are seeing positive momentum, and we are excited about the opportunity to make FRE a material contributor to revenue and profit growth in the Stoker's segment, buoyed by a category that's already worth over $2 billion in annual wholesale revenue and grew over 50% last year for MSAi.
We are currently focusing on prudently ramping up our sales and distribution efforts to achieve steady growth over time. We are leveraging our sales and distribution expertise to profitably expand FRE's profile and store count similar to what we've achieved with Stoker's MST over time.
In addition to our traditional channel, we are also seeing alt channel demand for our FRE Modern Oral nicotine product, even if many of these stores don't sell traditional tobacco products. I mentioned this because the dynamic may not be intuitive for some of you, but it speaks volume to the synergies that TPB brings to bear with our world-class sales, service and distribution platform. We look forward to providing updates on this exciting new product in the quarters and years to come.
Given our solid start to the year, we are reaffirming our guidance for projected 2024 adjusted EBITDA in the range of $95 million to $100 million. Of note, our guidance range contemplated no contribution from CDS, which generated approximately $600,000 of adjusted EBITDA during the first quarter and about $2 million full year EBITDA in 2023. A reminder that last year, we closed on our ABL facility, which with cash on hand and free cash flow generation gives us ample liquidity to address our convert maturity this summer, while providing flexibility for capital deployment.
With that, let me hand the call over to Summer to walk through some progress and results of some of our specific go-to-market initiatives.